secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2024-07-12T23:59:59+00:00
Accession:  0001104659-24-079596
Event type: debt
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.03, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical increases credit facility to $25M, appoints new director Michael C. Pearce
--------------------------------------------------------------------------------

- Credit facility increased from $20M to $25M; additional $5M available upon FDA approval of DFD-29 by June 30, 2025.
- Term loan matures Dec 27, 2027; interest = 3-month SOFR (floor 5%) + 7.75%.
- Principal repayment starts Feb 2026 at 7.5% quarterly; delayed if trailing revenue >$70M as of Dec 2025.
- Appointed Michael C. Pearce to Board (size now six); receives 30,000 RSUs, $50K annual RSU grant, $50K cash retainer.
- Adopted non-qualified deferred compensation plan for non-employee directors and select executives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924079596/0001104659-24-079596-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465924079596/tm2419378d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-079596

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer